Chong Kun Dang Pharmaceutical Corp.
185750 | KO
Overview
Corporate Details
- ISIN(s):
- KR7185750007
- LEI:
- Country:
- South Korea
- Address:
- 서울 서대문구 충정로3가 3가 368 종근당빌딩, 서대문구
- Website:
- https://www.ckdpharm.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 승인)
|
Korean | 7.2 KB | ||
| 2025-08-22 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 13.5 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.9 MB | ||
| 2025-08-01 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-07-24 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-06-24 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 99.9 KB | ||
| 2025-06-12 00:00 |
Regulatory Filings
유형자산취득결정
|
Korean | 7.9 KB | ||
| 2025-06-12 00:00 |
Regulatory Filings
풍문또는보도에대한해명(미확정)
|
Korean | 8.0 KB | ||
| 2025-06-10 00:00 |
Regulatory Filings
풍문또는보도에대한해명(미확정)
|
Korean | 6.2 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 1.8 MB | ||
| 2025-05-22 00:00 |
Regulatory Filings
기타경영사항(자율공시) (CKD510 기술수출 관련 마일스톤 수령)
|
Korean | 5.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.9 MB | ||
| 2025-04-30 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-04-23 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (듀비엠폴서방정(CKD383) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 16.9 KB | ||
| 2025-04-23 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (듀비엠파정(CKD398) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 16.6 KB |
Automate Your Workflow. Get a real-time feed of all Chong Kun Dang Pharmaceutical Corp. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Chong Kun Dang Pharmaceutical Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Chong Kun Dang Pharmaceutical Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
South Korea
068270
South Korea
049180
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
Poland
CLN
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
United States of America
CELU
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
United States of America
CNTA
Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.
United States of America
IPSC
United States of America
IPSC
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden
CRNO
Sweden
CRNO
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
United States of America
CERO
Develops pathogen reduction technology to safeguard the global blood supply for healthcare providers.
United States of America
CERS
United States of America
CERS